Abstract. Estrogen (E2) has long been implicated in epithelial ovarian cancer (EOC) progression. The effects of E2 on cancer progression can be mediated by numerous target genes, including coding RNAs and, more recently, non-coding RNAs (ncRNAs). Among the ncRNAs, long ncRNAs (lncRNAs) have emerged as new regulators in cancer progression; therefore, our aim was to determine whether the expression of any lncRNAs is regulated by E2 and, if so, whether a subset of these lncRNAs have some clinical significance in EOC progression. A microarray was performed to identify E2-regulated lncRNAs in E2 receptor (ER) α-positive EOC cells. Bioinformatics analyses of lncRNAs were conducted, focusing on Gene Ontology and pathway analyses. Quantitative real-time polymerase chain reactions were performed to confirm the expression of certain lncRNAs in ERα-positive EOC tissues. The correlation between certain lncRNA expression and clinicopathological factors as well as prognosis in ERα-positive EOC patients was then analyzed. We showed that 115 lncRNAs exhibited significant changes in E2-treated SKOV3 cells compared with untreated controls. Most of these lncRNAs were predicated to have potential to contribute to cancer progression. Notably, three candidates (TC0100223, TC0101686 and TC0101441) were aberrantly expressed in ERα-positive compared to ERα-negative EOC tissues, showing correlations with some malignant cancer phenotypes such as advanced FIGO stage and/or high histological grade. Furthermore, multivariate analysis indicated that TC0101441 was an independent prognostic factor for overall survival. Taken together, these results indicate for the first time that E2 can modulate lncRNA expression in ERα-positive EOC cells and that certain lncRNAs are correlated with advanced cancer progression and suggestive of a prognostic indicator in ERα-positive EOC patients. Knowledge of these E2-regulated lncRNAs could aid in the future understanding of the estrogenic effect on EOC progression and may assist in the clinical design of new target therapies based on a perspective of lncRNA.
Introduction
Epithelial ovarian cancer (EOC) is the most deadly malignancy of the female reproductive tract in many countries (1, 2) . Involvement of steroid hormones, primarily estrogen, has been associated with EOC. Ample evidence from epidemiologic, clinical and experimental research has demonstrated that E2 is responsible for promoting EOC progression (3) (4) (5) (6) (7) (8) (9) . Although the effects of E2 on EOC progression have been extensively studied, the underlying mechanisms remain unknown and the clinical response to steroid hormone therapy remains disappointing. Thus, fully identifying the contributions of E2 to EOC progression is urgently required.
Compelling data have demonstrated that the effects of E2 on EOC development are mediated by the regulation of target genes involved in the control of cancer progression. Previous studies, including ours, have identified a panel of aberrantly expressed E2-regulated protein-coding genes that are involved in cellular growth control, such as cyclin D1 and c-myc, and in cellular metastasis control, such as fibulin-1, cathepsin-D, HIF-1, nm23-H1, E-cadherin and MMP-2 (4) (5) (6) (7) 10, 11) . Despite these protein-coding genes, undoubtedly, the set of genes that directly mediate estrogenic effects on EOC progression has not been fully defined. Therefore, exploration of new E2-regulated genes is needed, which may help elucidate estrogenic effects on EOC progression and provide optional therapeutic targets.
The human transcriptome was found to be more complex than a collection of protein-coding genes, showing extensive non-coding RNA (ncRNA) expression (12 (lncRNAs; >200 nt in length), initially argued to be spurious transcriptional noise (13) , are emerging as new regulators in the cancer paradigm. Aberrant expression of lncRNAs has been reported to be associated with malignant phenotypes in various human tissues, and some lncRNAs, such as HOTAIR, MALAT-1, H19, HuLC, lincRNA-p21 and MEG3, might also function as tumor suppressor genes or oncogenes (14) (15) (16) (17) (18) (19) .
Although several published studies have reported lncRNAs such as lncRNA-LSINCT5 and HOST2 in EOC (20, 21) , to our knowledge, no studies have focused on E2-regulated lncRNAs in EOC. Therefore, we sought to identify E2-regulated lncRNAs in EOC. We found that E2 stimulation of ERα-positive (ERα+) EOC cells resulted in a panel of differentially expressed lncRNAs, showing great potential to contribute to cancer progression based on bioinformatics analyses. Moreover, we found that some candidate lncRNAs were aberrantly expressed in ERα+ compared to ERα-negative (ERα-) EOC tissues, and their differential expression was associated with certain clinicopathological variables and poor prognosis of ERα+ EOC patients. Our results highlight for the first time the potential use of lncRNAs as causal link with estrogenic effects on EOC progression and as surrogate targets to hormone therapy.
Materials and methods

Cells and treatment.
The ovarian cancer cell line SKOV3 was obtained from the American Type Culture Collection (ATCC; Manassas, VA, uSA). SKOV3 cells were routinely maintained in RPMI-1640 medium (Gibco-BRL, Gaithersburg, MD, uSA) supplemented with 10% fetal bovine serum (FBS; Gibco) and maintained at 37˚C with 5% CO 2 . For the E2 induction experiments, cells (plated at 20-30% confluence) were grown for 3 days in phenol red-free RPMI-1640 (Gibco) containing 5% activated, charcoal-treated foetal bovine serum (Serana, Bunbury, Australia). Next, the cells were treated for 24 h with 10 -8 M E2 or vehicle alone (DMSO, 0.01% of final volume) as a control.
RNA extraction and microarray. TRIzol (Invitrogen, Carlsbad, CA, uSA) was used to extract total RNA from SKOV3 cells with or without 24-h treatment with 10 -8 M E2. There were three replicates of each sample; they were purified using an RNeasy Micro kit (cat. #74004; Qiagen GmbH, Hilden, Germany). An Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, uSA) was used to quantify the RNA and evaluate its integrity; the 28S:18S ratio was determined, and an RNA integrity number (RIN) was assigned to each sample. RNA with no evidence of degradation and no signs of DNA contamination (as indicated by an RiN ≥7.0 and a 28S:18S ratio ≥0.7) was processed for further analysis.
The lncRNA and mRNA expression profiles were obtained using the Glue Grant Human Transcriptome (GG-H) Array, which was manufactured by Affymetrix and Stanford university. This array contains 5,869 probes covering 730 non-coding, functional RNAs and 3,292,929 probes covering 27,670 coding genes collected from RefSeq, Ensembl and uCSC Known Genes, based on human genome assembly hg18 (22) . The array experiments and computational analysis were performed according to the manufacturer's instructions (Affymetrix, Santa Clara, CA, uSA). Briefly, 0.2 µg of total RNA was amplified and labelled, and 20 µg of labelled cDNA was loaded onto the array. The array was hybridized and washed using the GeneChip ® Hybridization, Wash and Stain kit (cat. #900720), Hybridization Oven 645 (cat. #00-0331-220V) and Fluidics Station 450 (cat. #00-0079). The slides were scanned in a GeneChip ® Scanner 3000 (cat. #00-00212). The raw data were obtained using Command Console Software 3.1 with the default settings and were processed using Affymetrix Power Tools with Robust Multiarray Analysis (RMA) for background correction, normalization and summarization. Differentially expressed genes [defined as a fold-change ≥1.5 and a P-value <0.05 (t-test)] were selected for further study.
Bioinformatics functional analysis of E2-regulated lncRNAs
Identification of lncRNA-mRNA targeting pairs. Two procedures were performed to search for the target mRNAs of lncRNAs. First, uCSC hg18 (http://genome.ucsc.edu/) was used to predict lncRNA targets. Target genes under cis-regulatory control were defined as genes whose transcription was regulated by lncRNAs in nearby genomic locations (≤10 kbp upstream or downstream) (23) . Based on mRNA sequence complementarity and RNA duplex energy prediction, transacting target genes were identified using BLAST software in the first round of screening (with the parameter e <1E-5) and RNAplex software for final verification (with the parameter -e -20) (24) . Additionally, to improve the accuracy of the target prediction, the predicted lncRNA targets (both cis and trans) were combined with the differentially expressed mRNAs in the profile. The resultant overlapping mRNAs were considered the final putative targets of the differentially expressed lncRNAs. This information formed the basis for determining the lncRNA-mRNA targeting pairs.
Gene ontology (GO) and pathway analysis. For the GO and pathway analyses, the putative targets were initially inputted into the Database for Annotation, Visualization and integrated Discovery (DAViD, http://david.abcc.ncifcrf.gov/), which searched the GO terms to identify the molecular function represented in the gene profile (25) , and then into the database of the Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.ad.jp/kegg/) to analyze the roles of the targets in molecular pathways (26) . Immunohistochemistry. The immunohistochemical study of ERα was performed using a standard streptavidin-peroxidase method. The endogenous peroxidase activity was blocked with 3% H 2 O 2 for 10 min. For the antigen retrieval, slides were immersed in 10 mM citrate buffer (pH 6.0) and boiled for 15 min in a microwave oven. Non-specific binding was blocked by 5% normal goat serum for 10 min. The slides were incubated with a 1:50 dilution of monoclonal antibody against ERα (Santa Cruz Biotechnology, Santa Cruz, CA, uSA) at 4˚C overnight in a moist chamber. The slides were sequentially incubated with biotinylated goat anti-mouse IgG (1:100 dilution; Santa Cruz Biotechnology) and then streptavidin-peroxidase conjugate, each for 30 min at room temperature. Isotope-matched human IgG was used in each case as a negative control. Finally, the 3,5-diaminobenzidine (DAB) Substrate kit (Dako) was used for color development followed by Mayer's hematoxylin counterstaining. ERα+ cases were defined as tumors with >10% stained nuclei (27) .
Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR).
qRT-PCR analysis of lncRNA expression was performed using FastStart universal SYBR-Green Master (Rox; Roche) and an ABI Prism 7900 Real-Time PCR system (Applied Biosystems, Foster City, CA, uSA). Briefly, total RNA was extracted from cells and tissues and converted to cDNA using an iScript cDNA Synthesis kit (Bio-Rad Laboratories) according to the manufacturer's protocol. The PCR amplifications were performed in a 10-µl (total volume) reaction that included 1 µl of cDNA template (~5 ng), 5 µl of FastStart universal SYBR-Green Master (Rox), 3.6 µl of double-distilled water and 0.2 µl of each pair of forward and reverse primers (Table I ; Sangon Biotech Co., Ltd., Shanghai, China). The PCR conditions included an initial denaturation step at 95˚C for 10 min and 40 cycles of 95˚C for 15 sec and 60˚C for 30 sec. All the experiments were performed in triplicate, and all the samples were normalized to GAPDH expression. The expression fold-changes were calculated using the 2 -ΔΔCt method.
Statistical analysis. The data were processed using SPSS version 16.0 software (SPSS, Inc., Chicago, IL, uSA).
Comparison of continuous data was analyzed using the Student's t-test, whereas categorical data was analyzed using the Chi-square test and Fisher's exact test where appropriate (when the expected frequency was <5). OS curves were plotted according to the Kaplan-Meier method, with the log-rank test applied for comparison. Variables were used in multivariate analysis on the basis of the Cox proportional hazards model. A P-value <0.05 was considered to indicate a statistically significant difference (P<0.05).
Results
Identification of E2-regulated lncRNAs in ERα+ ovarian cancer cells Identification of E2-regulated lncRNAs in SKOV3 cells.
As our previous studies provided evidence that E2 regulated some protein-coding genes in ERα+ ovarian cancer SKOV3 cells (5-7), we examined whether the expression of any lncRNAs is also regulated by E2 in SKOV3 cells. in the present study, SKOV3 cells were treated with 10 -8 M E2 for 24 h, and changes in the lncRNA expression profile were analyzed by performing a microarray. The microarray data indicated that 115 lncRNAs were significantly dysregulated following E2 treatment, including 51 upregulated and 64 downregulated lncRNAs (fold-change ≥1.5, P<0.05; data not shown). The top ten relative increased and decreased E2-regulated lncRNAs are listed in Table II .
To confirm the microarray findings, we examined the expression of four lncRNAs selected from the top ten relative increased and decreased E2-regulated lncRNAs using qRT-PCR. The results revealed that the expression levels of TC0100223 and TC0101686 were significantly downregulated by E2, whereas TC1500845 and TC0101441 were significantly upregulated by E2 in SKOV3 cells, consistent with the microarray results (Fig. 1) .
Putative targets of E2-regulated lncRNAs and their functional analysis.
Based on the overlap between the targets predicted by bioinformatics and the differentially expressed mRNAs detected in the microarray, we constructed 55 E2-regulated lncRNA-target mRNA pairs (Table III) . The GO (Fig. 2) and pathway (Table iV) analyses showed that a set of E2-regulated lncRNAs that mapped to the target mRNAs were correlated with several cellular processes and pathways known to be related to cancer progression, such as cell cycle and proliferation, developmental processes, cell adhesion, cell death, MAPK signaling, Hedgehog signaling, Jak-STAT signaling and cancer pathways, suggesting their great potential to contribute to cancer progression.
Expression of several candidate lncRNAs in ERα+ EOC
tissues. in order to confirm the potential of some E2-regulated lncRNAs to contribute to cancer progression, we initially selected the four lncRNAs (TC0100223, TC0101686, TC1500845 and TC0101441) as candidates and tested their expression levels in EOC tissues. Considering the fact that ERα is the main form expressed in malignant ovarian tumors and as ERα has been reported to promote poor prognosis in EOC patients (28,29), we determined whether the expres- TC1400062  ABHD4  cis 22136986  22151097  +  chr14  11599456  11603583  +  chr12  TC1200137  TAS2R7  cis 10845399  10846493  -chr12  7154170  7159091  +  chr12  TC1200076  CDCA3  cis 6824224  6830686  -chr12  7154170  7159091  +  chr12  TC1200076  CLSTN3  cis 7174234  7202795  +  chr12  7154170  7159091  +  chr12  TC1200076  ING4  cis 6629707  6642565  -chr12  7154170  7159091  +  chr12  TC1200076  PTPN6  cis 6926001  6940741  +  chr12  6966612  7033762  +  chr12  TC1200074  CDCA3  cis 6824224  6830686  -chr12  6966612  7033762  +  chr12  TC1200074  CLSTN3  cis 7174234  7202795  +  chr12  6966612  7033762  +  chr12  TC1200074  ING4  cis 6629707  6642565  -chr12  6966612  7033762  +  chr12  TC1200074  PTPN6  cis 6926001  6940741  +  chr12  5383589  5384883  +  chr12  TC1200045  NTF3  cis 5473527  5474725  +  chr12  58457692  58582501  -chr11  TC1101435  STX3  cis 59279108  59326752  +  chr11  18821244  18823011  +  chrX  TC0X00076  GPR64  cis 18917348  19050676  -chrX  66450847  66456323  -chr9  TC0900981  PiK3C2B  trans 2.03E+08  202730566  -chr1  12264367  12270292  +  chr8  TC0800087  DLC1  cis 12985243  13506486  -chr8  12264367  12270292  +  chr8  TC0800087  CTSB  cis Association of lncRNA expression with clinicopathological characteristics in ERα+ EOC. According to the median value which was used as the cut-off (30), specific lncRNA expression in ERα+ EOC tissues, equal or more than median value was defined as high lncRNA group, and less than median value was defined as low lncRNA group. As shown in Table V , low-expression of TC0100223 and TC0101686 and high-expression of TC0101441 were closely related to ERα+ EOC tissues with advanced FIGO stage and/or high histological grade (P<0.05), suggesting that aberrant expression of the three candidate lncRNAs is associated with a more malignant ovarian cancer phenotype. Fig. 4 shows the OS curves according to TC0101441 expression). Thus, it was concluded that of the three candidate lncRNAs, TC0101441 could be used as an independent prognostic factor for OS of ERα+ EOC patients. 
Information of mRNAs ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Cases (N) n (%) P-value n (%) P-value n (%) P-value 
Discussion
In the present study, we identified a series of differentially expressed E2-regulated lncRNAs in ERα+ ovarian cancer SKOV3 cells using a microarray. Bioinformatics functional analyses indicated that a fraction of these lncRNAs had the potential to contribute to cancer progression. Furthermore, in order to confirm that some E2-regulated lncRNAs are related to the development of ERα+ EOC, we tested the expression of several candidate lncRNAs in EOC tissues. The results showed that some candidate lncRNAs were aberrantly expressed in ERα+ compared to ERα-EOC tissues, and their differential expression was associated with certain clinicopathological variables and poor prognosis of ERα+ EOC. To the best of our knowledge, this is the first study to report E2-regulated lncRNAs in ERα+ EOC, the results of which may provide insight into the estrogenic effects on EOC progression and the design of new target therapies based on a perspective of lncRNA. It is known that the ovary is a main source and target tissue of E2 in women. The action of E2 on ovarian tissue is believed to be mediated by the two ERs, ERα and ERβ. ERβ is highly expressed in normal epithelial ovarian cells and benign tumors, whereas ERα is expressed to a much greater extent in malignant ovarian tumors (28) . Several studies thus far have revealed the contributions to EOC progression by multiple E2/ERα-regulated target protein-coding genes, such as cyclin D1 and c-myc (which are involved in cellular growth control) and fibulin-1 and cathepsin-D (which are involved in cellular motility and invasion) (10, 11) .Our previous studies also showed that E2 promoted metastasis and invasion in ERα+ ovarian cancer SKOV3 cells by regulating HIF-1, nm23-H1, E-cadherin and MMP-2 (5-7). Despite these protein-coding genes, however, the exact effects of E2 on EOC development remain unclear. In the present study, we identified 115 E2-regulated lncRNAs in ERα+ SKOV3 cells using a microarray, and subsequent bioinformatics analyses indicated that a subset of these lncRNAs had the potential to contribute to cancer progression. These findings may extend our current knowledge regarding E2 regulation of protein-coding genes in EOC progression to include lncRNAs. lncRNAs, initially argued to be spurious transcriptional noise, are emerging as new regulators in the cancer paradigm. Misregulation of lncRNAs has been documented in many types of human cancer. For example, DDC and PCGEM are overexpressed in prostate cancer compared to normal prostate tissue, implicating their roles in tumorigenesis (31, 32) . Increased expression of MALAT1 indicates a poorer clinical outcome of lung cancer patients (15) . HOTAIR is overexpressed in primary breast tumors and metastases, and elevated HOTAIR expression is an indispensable predictor of eventual metastasis and mortality (14) . Inspired by these lines of evidence of lncRNA roles in cancer biology, we hypothesized that certain E2-regulated lncRNAs detected in SKOV3 cells in the current study may also have the potential to contribute to EOC progression. To address this hypothesis, we initially tested two upregulated (TC1500845 and TC0101441) and two downregulated lncRNAs (TC0100223 and TC0101686) in EOC tissues, the results of which showed a significant correlation of overexpressed TC0101441 and lowexpressed TC0100223 and TC0101686 with ERα+ compared to ERα-EOC. Moreover, low-expression of TC0100223 and TC0101686 and overexpression of TC0101441 were found to be related to ERα+ EOC tissues with advanced FIGO stage and/or high histological grade. Most importantly, multivariate survival analysis revealed that TC0101441 was an independent prognostic factor for overall survival. Taken together, our findings suggest that the aberrant expression of certain E2-regulated lncRNAs is associated with malignant cancer phenotypes and poor clinical outcome of ERα+ EOC patients. Hence, these results may also lead us to consider that E2-regulated lncRNAs can be used as candidate biomarkers for EOC prognosis and therapy. Clearly, further studies are required to elucidate the roles and mechanisms by which these lncRNAs promote EOC development in detail.
in conclusion, the present study provided the first evidence that E2 can modulate a panel of lncRNAs in ERα+ EOC cells. Some aberrantly expressed lncRNAs, including TC0100223, TC0101686 and TC0101441, are correlated with the advanced cancer phenotypes. Of note, TC0101441 was an independent factor for poor prognosis of ERα+ EOC patients. Collectively, encouraged by the involvement of these E2-regulated lncRNAs in ERα+ EOC progression, our data highlight the utility of considering lncRNA expression in the future understanding of estrogenic effects on EOC progression and in the design of new target therapies.
